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Background: The management of patients with abdominal aortic aneurysm (AAA) and concurrent malignancy is
controversial. This study retrospectively assessed the outcome of endovascular repair (EVAR) and open repair (OR) for
the treatment of AAA in patients undergoing curative treatment for concomitant malignancies.
Methods: All patients who underwent surgery for a nonruptured infrarenal AAA of>5.5 cm and concomitant malignancy
between 1997 and 2005 were retrospectively reviewed.
Results: Identified were 25 patients (22 men; mean age, 70.3 years) with nonruptured infrarenal AAA of >5.5 cm (mean
size, 6.4 cm) and concomitant malignancy amenable for curative treatment. EVAR was used to treat 11 patients, and 14
underwent OR. The EVAR patients had a smaller mean aneurysm size (5.9 cm vs 6.8 cm; P .006) than the OR patients.
Themean cumulative length of stay for all patients who received treatment for both AAA and cancer was 12.8 days (range,
4 to 26) for EVAR and 18.2 days (range, 9 to 42 days) for OR. In the EVAR group, no patients died perioperatively; in
the OR group, three patients died perioperatively (21.4%; P NS). Postoperative complications occurred in one patient
in the EVAR group and in seven in the OR group for a morbidity rate, respectively, of 9.1% and 50% (P  .04). One late
complication (9.1%) occurred in the EVAR group. The mean follow-up was 37.7 months (range, 16 to 60 months) in the
EVAR group and 29.6 months (range, 11 to 55 months) in the OR group. At 1 and 2 years, survival rates were 100% and
90.9% in the EVAR group and 71.4% and 49% in the OR group (log-rank P  .103)
Conclusions: With low morbidity and mortality, EVAR is a safe technique for the treatment of AAA in patients with
concomitant malignancy and could be considered as an alternative to OR. (J Vasc Surg 2007;46:16-23.)Cross-sectional imaging and, in particular, computed
tomography (CT) scanning is increasingly being used in the
preoperative investigations of patients for a variety of pa-
thologies, including cancer and abdominal aortic aneurysm
(AAA), and is likely to increase the proportion of patients in
whom the two conditions are found to coexist.1 Although
the true incidence is difficult to establish, it has been
reported to be as high as 13.4%.2-4 These patients present a
therapeutic dilemma, and their management is controver-
sial.5-7 In those fit to undergo major surgery, one of three
strategies might be adopted: (1) to repair the aneurysm first
and resect the malignancy later, (2) to treat the malignancy
first and repair the aneurysm later, or (3) to undertake both
procedures under the same anesthesia.
Many authors have reported excellent results in patients
who have undergone open AAA repair combined with
resection of a malignancy with curative intent. This ap-
proach avoids delay in the treatment of either pathology
andminimizes the risk that one or the other will progress or
give rise to complications in the interim between two
operations.8-11
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16Advocates of the combined approach argue that there
appears to be an increased risk of aneurysm rupture in the
immediate aftermath of other major operations. Rupture of
the AAA after laparotomy for an unrelated condition may
occur because of collagen lysis induced by operation itself
or may be due to weakening of the aneurysm wall from
nutritional depletion and surgical dissection.12,13 Cortico-
steroid administration and chemotherapy, if required post-
operatively for associated malignancy, may also contribute
to aneurysm enlargement and rupture.14 Potential mecha-
nisms may involve inhibition of smooth muscle cell prolif-
eration and collagen and elastin synthesis, and a blood
volume increase from hydration included in chemothera-
peutic protocols.15
A concern when treating both pathologies during the
same intervention is the risk of aortic graft infection, espe-
cially in patients undergoing procedures in which there is
contamination. However, successful outcomes have been
reported for procedures combining treatment for both
AAA and colorectal cancer4,16-20 as well as for AAA and
bladder cancer.21 Furthermore the aggregate risk of a
staged aneurysm repair and cancer resection has not been
shown to be lower than the risk of a single combined
procedure, whereas from the patient’s point of view, having
one operation rather than two is likely to be preferable.
Because of all these uncertainties, there is no consensus
on the best therapeutic approach for patients with simulta-
neous AAA and malignancy. In the past, surgical strategy
has been determined by the patient’s general condition, the
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rysm size, and the cancer features and stage.3-7
Although the long-term effectiveness of endovascular
aneurysm repair (EVAR) is still controversial,22,23 and
some authors consider the presence of a concurrent malig-
nancy a contraindication to the EVAR,24,25 this technique
has recently been proposed as a treatment option for pa-
tients with AAA and coexistent malignancy. A few small
series and reports have described the successful use of
EVAR in patients with synchronous colorectal, renal, lung,
esophageal, pancreatic, and bladder cancer (Table I).26-31
To our knowledge, however, no studies to date have com-
pared the results of EVAR and open repair (OR) for the
treatment of patients with concomitant AAA and malig-
nancy. The aim of this study was to assess retrospectively
the outcome of EVAR and OR for the treatment of AAA in
patients undergoing curative treatment for concomitant
malignancy.
PATIENTS AND METHODS
A retrospective review was done of all patients admitted
with a diagnosis of a nonruptured infrarenal AAA of 5.5
cm and concomitant malignancy to the Department of
General and Vascular Surgery of the Federico II University
of Naples (UN), Italy, and the Department of Surgery of
Whipps Cross University Hospital, London, United King-
dom, during an 8-year period (1997-2005). Only patients
who were considered suitable for cancer treatment with
curative intent were included in the study.
Data were collected through hospital chart review.
Including criteria were nonruptured AAA 5.5 cm, AAA
repair (OR or EVAR), and concomitant malignancy treated
with curative surgical intervention with or without adjuvant
therapy. Patient data collected were age, sex, smoking
history, comorbidity (hypertension, diabetes, chronic ob-
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EVAR, Endovascular aneurysm repair; NS, not stated.structive pulmonary disease, coronary artery disease, cere-brovascular disease, renal failure), aneurysm size, cancer
(type, location, and stage), cancer treatment and timing,
type of anesthesia, postoperative length of stay, periopera-
tive mortality and morbidity, survival outcome, and cause
of death.
Operative risk was assessed according to The American
Society of Anesthesiologists (ASA) physical status classifi-
cation.32 All tumors were staged according to the TNM
classification system.33 Indications for EVAR were based
on the agreed criteria for the European Collaborators on
Stent-Graft Techniques for Abdominal Aortic Aneurysm
Repair (EUROSTAR) trial.34 EVAR was offered to all
patients clinically considered suitable.
Baselines characteristics of the EVAR and OR groups
and 30-day morbidity and mortality were compared using
the two-tailed t test for continuous variables and the 2 or
Fisher’s exact test for categoric data. Cumulative survival
rate at 1 and 2 years were analyzed using the Kaplan-Meier
method and log-rank test.
RESULTS
We identified 25 patients (22 men; 17 from the UN),
with a mean age of 70.3 years (range, 58 to 84 years), who
had a nonruptured infrarenal AAA of 5.5 cm (range, 5.6
to 9 cm; mean size, 6.4 cm) and a concomitant malignancy
amenable for curative treatment. The malignancy origi-
nated from the urinary tract in 12 (48%), including two
prostatic cancers, six bladder cancers, and four renal can-
cers. Nine patients (36%) had colorectal cancer, three (12%)
had lung cancer, and one (4%) had pancreatic cancer. In 14
patients (56%), the cancer was an incidental finding on CT
scanning for AAA assessment. In the other 11 (44%), the
aneurysm was found during investigations for symptomatic
malignancy. There were no cases of intraoperative acciden-



























evental diagnosis of tumor or AAA.
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EVAR was done in 11 (44%; 9 men; Table II) and OR in 14
(56%; 13 men; Table III). The mean patient age was 71.3
years (range, 59 to 84 years) in the EVAR group and 69.6
years (range, 58 to 83 years) in OR group (P  NS). No
significant differences were observed in other patient de-
mographics, comorbidity, risk factors, and ASA grade be-
tween the two groups. Aneurysm size was larger in the OR
group (mean, 6.8 cm vs 5.9 cm; P  .006; Table IV).
Patients in the EVAR group were followed up at 1, 6,
and 12 months with CT scan and then every year with a
duplex scan. Patients in OR group were followed up at 6
and 12 months and annually thereafter.
The cancer was surgically resected in all patients treated
with EVAR and in 12 (85.7%) of the 14 patients in the OR
group because two patients in the latter group died after the
AAA repair.
All the EVAR procedures occurred before the onco-
logic treatment, and all patients in this group were treated
in two different admissions. The mean interval between the
two procedures was 6.5 days (range, 2 to 11 days). In the
OR group, the AAA and cancer were treated with a one-
stage procedure in seven patients (50%). Five patients
(35.7%) underwent a two-stage treatment, in all cases with
two different hospital admissions; in four, the AAA was
treated first. The last patient underwent an abdominoperi-
neal excision of the rectum as the initial treatment, followed
by adjuvant chemotherapy. The AAA enlarged, became
symptomatic, and required urgent repair 82 days after the
original operation. Two patients (14.3%) died after the
AAA repair and never received cancer treatment (Table
III).
The mean AAA diameter in EVAR patients was 5.9 cm
(range, 5.6 to 6.5 cm). Talent grafts (Medtronic, Minne-
apolis, Minn) were placed in 4 patients, Excluder grafts
(W. L. Gore & Associates, Flagstaff, Ariz) in 3, Zenith
grafts (Cook, Bloomington, Ind) in 3, and an AneuRx graft
(Medtronic) in 1. Device configuration included 10 bifur-
cated grafts and one aortouniiliac graft, combined with
femorofemoral bypass repair. Eight patients had infrarenal
fixation of the endografts, and three patients had transrenal
fixation. Epidural anesthesia was used in nine patients and
local anesthesia in two.
In the OR group, the mean AAA diameter was 6.8 cm
(range, 5.8 to 9 cm). Fourteen aortic reconstructions con-
sisted of nine straight grafts, three aortobiiliac grafts, and
two aortobifemoral bypass grafts, all through a transperito-
neal approach.
The mean postoperative length of stay (LOS) for the
AAA repair was 4.3 days (range, 2 to 7 days) in the EVAR
group and 9.2 days (range, 8 to 11 days) for the five
patients in theOR groupwho had a two-stage procedure (P
 .001). The LOS for the cancer treatment was 8.5 days
(range, 2 to 19 days) in the EVAR group and 13.2 days
(range, 3 to 34 days) for theOR group (PNS). Themean
interval between the two procedures in the five patients in
the OR group who had two-stage procedure was 23 days
(range, 14 to 35), which was significantly longer than theEVAR group (P  .05). In the seven patients that had a
one-stage procedure, the average LOS was 19 days (range,
9 to 23). The last two patients planned for a two-stage
approach died 4 and 18 days after the AAA repair. The
cumulative LOS for all patients who received treatment for
both AAA and cancer was 12.8 days (range, 4 to 26 days)
for EVAR and 18.2 days (range, 9 to 42 days) for OR.
No patients in the EVAR group died perioperatively.
Three patients (21.4%) in the OR group died periopera-
tively (P  NS), one each from disseminated intravascular
coagulopathy, cardiac failure, and sepsis. Postoperative
complications occurred in one patient in the EVAR group
and in seven in the OR group for a morbidity rate, respec-
tively, of 9.1% and 50% (P  .04).
The patient in the EVAR group with complication
underwent EVAR and left internal iliac artery coil emboli-
zation. This procedure was complicated by intraoperative
graft limb occlusion, which required conversion to an aor-
touniiliac graft and femorofemoral bypass grafting. The
patient recovered well and underwent an anterior resection
of the rectum 11 days later. An anastomotic leak developed
5 days after the operation, which required the formation of
a temporary stoma. No sign of endograft infection devel-
oped, but the patient died of metastasis 39 months later.
The seven major postoperative complications in the OR
group included one retroperitoneal bleeding, three acute
myocardial infarctions, two colonic anastomotic leaks, and
a graft infection. In the EVAR group, one late complication
(9.1%) occurred when graft limb thrombosis developed in a
patient at 14months, which required reintervention. There
were no late complications in the OR group.
The mean follow-up was 37.7 months (range, 16 to 60
months) in the EVAR group and 29.6 months (range, 11
to 55months) in theOR group. During the follow-up, four
patients in the EVAR group and five in the OR group died.
In the EVAR group, two deaths were cancer-related
(18.2%) and two (18.2%) were secondary to a cardiac event.
In the OR group, four patients (28.6%) died of cancer and
one (7.1%) died at 23 months of prosthetic graft infection
after a left hemicolectomy, despite an attempted salvage
procedure. The 1-year and 2-year survival rates were 100%
and 90.9% in the EVAR group and 71.4% and 49% in the
OR group (log-rank P  .103; Fig).
DISCUSSION
When treating patients with AAA and concurrent ma-
lignancy, the surgical approach and timing for the AAA
repair remain very controversial. Decision-making may de-
pend on many variables, including surgeon experience and
preference, local expertise, aneurism size, and type and
stage of cancer. Although our study might not resolve the
dilemma about which strategy is best in patients needing
both aneurysm repair and resection of a malignancy, to our
knowledge, it is the first to compare the results of EVAR
and OR in the management of patients with concomitant
AAA and malignancy.
In our study, seven of the 14 patients in the OR group
had a combined procedure, with one death secondary to a













82 M 5.7 Excluder,* bifurcated, IFX Bladder II Transurethral
resection, local
chemo
Yes 2 Endograft limb occlusion
(14 mo)
2/2 Alive (60 mo)
72 M 6.4 Zenith,† bifurcated, IFX Pancreas II Total
pancreatectomy,
chemo
Yes 9 7/11 Died: metastases (25 mo)
59 M 5.8 Zenith,† bifurcated, IFX Left colon II Left
hemicolectomy
Yes 5 4/10 Died: stroke (46 mo)
73 F 6.1 AneuRX,‡ bifurcated, IFX Right colon III Right
hemicolectomy,
chemo
Yes 6 5/8 Alive (50 mo)
68 M 5.8 Excluder,* bifurcated, IFX Bladder III Radical
cystectomy,
chemo
Yes 6 5/11 Alive (55 mo)
65 M 5.6 Excluder,* bifurcated, IFX Prostate II Prostatectomy,
hormonal/chemo
Yes 7 4/7 Alive (40 mo)
74 M 5.9 Talent,‡ aortouniiliac, IFX Rectum III Anterior resection Yes 11 Intraop. endograft limb
occlusion; colonic
anastomotic leak
7/19 Died: metastases (39 mo)
71 F 5.7 Talent,‡ bifurcated, TFX Kidney III Nephrectomy,
interferon
therapy
Yes 6 2/7 Alive (32 mo)




Yes 4 3/2 Alive (27 mo)
63 M 5.8 Talent,‡ bifurcated, IFX Prostate II Prostatectomy,
hormonal/chemo
Yes 8 4/9 Alive ( 25 mo)
84 M 6.5 Zenith,† bifurcated, IFX Left colon III Left
hemicolectomy/
chemo
Yes 7 4/8 Died: MI (16 mo)
AAA, Abdominal aortic aneurysm; IFX, infrarenal fixation; TFX, transrenal fixation; chemo, chemotherapy; MI, myocardial infarction.





















































70 M 5.8 Tube Bladder III Radical cystectomy Yes One stage 18 Alive (44 mo)
73 F 6.4 Aortobiiliac Kidney II Nephrectomy Yes One stage 9 Alive (41 mo)






Graft infection 8/34 Died: sepsis (23
mo)




4 Died: DIC (4 d)
71 M 6.0 Aortobiiliac Bladder II TUR/chemotherapy Yes 14 AAA
first
10/3 Alive (35 mo)
64 M 7.1 Tube Kidney II Nephrectomy Yes One stage 10 Alive (27 mo)
73 M 5.9 Aortobiiliac Bladder III Died after AAA
repair
? Dead MI 18 Died: cardiac
failure (18 d)





Yes One stage MI 15 Died: metastases
(15 mo)
72 M 7.6 Tube L Colon III L hemicolectomy Yes One stage Colonic
anastomotic
leak
28 Died: sepsis (28
d)





62 M 6.4 Tube Lung II Lobectomy Yes 28 AAA
first
MI 9/12 Died: metastases
(15 mo)





AAA rupture 11/10 Alive: (55 mo)
64 M 9.0 Tube R Colon II R hemicolectomy Yes One stage 13 Alive: (21 mo)
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Volume 46, Number 1 Porcellini et al 21complication of cancer surgery. The other seven were in-
tended to have staged procedures, but two died after the
first operation (AAA repair) and the cancer surgery was not
done. The difference in mortality between these two
groups is not significant, but even if it is real, it is offset by
the occurrence of one late death from a postoperative graft
infection in a patient who had a combined procedure. It is
therefore impossible from this small group of patients to
conclude whether a combined approach is preferable than a
staged one when treating the AAA with OR. With three
postoperative deaths in 14 patients who had OR, the over-
all mortality in this group appears high, although patients
with associated neoplastic condition might be expected to
have a higher surgical risk than that of patients reported in
large series of aneurysm repairs. Conversely, none of 11
patients who had EVAR died postoperatively. Major post-
operative complications were also higher in the OR group.
Furthermore, the patient who had a complication related to
the EVAR was still able to undergo surgical treatment for
the cancer 11 days later.
This apparent advantage of EVAR in patients with AAA
and concomitant malignancy needs to be seen in the con-
text of the recently published EVAR trials. In EVAR 1, the
30-day mortality of patients undergoing EVAR was 1.7%,
compared with 4.6% for OR (P  .007). After 4 years of
follow-up, all cause mortality in the two groups was similar,
but there was a persistent reduction in aneurysm-related
death in patients who had EVAR (4% vs 7%, P .04). This
was offset by a much higher incidence of complications in
those who had EVAR (41%) compared with those who had
OR (9%, P  .0001).35 However, a recent meta-analysis of
randomized controlled trials confirmed a reduction in the
30-day mortality (1.6 vs 4.7%) and showed a lower inci-
dence of major complications (cardiac, respiratory, renal,
Table IV. Patient demographics and comorbidity
conditions
Factor EVAR, n (%)* OR, n (%)* P
Patients (n) 11 14
Age, mean years 71.3 (59-84) 69.6 (58-83) NS
Male gender 9 (81.8) 13 (92.9) NS
Smoking history 8 (72.7) 9 (64.3) NS
Hypertension 6 (54.5) 7 (50) NS
Diabetes mellitus 1 (9.1) 0 (0) NS
COPD 2 (18.2) 1 (7.1) NS
CAD/MI 4 (36.4) 4 (28.6) NS
Cerebrovascular
disease
1 (9.1) 0 (0) NS
Renal failure 0 (0) 1 (7.1) NS
ASA III or IV 6 (54.5) 6 (42.9) NS
Aneurysm size,
median cm
5.9 (5.6-6.5) 6.8 (5.8-9.0) .006
EVAR, Endovascular aneurysm repair;OR, open repair;NS, not significant;
COPD, chronic obstructive pulmonary disease; CAD, coronary artery dis-
ease;MI,myocardial infarction;ASA, American Society of Anesthesiologists
classification.
*Categoric data presented as number (%), continuous data presented with
the range.and hemorrhagic) after EVAR. Furthermore, hospital staywas shorter in the EVAR group, thus suggesting a quicker
recovery after this procedure.36
Similar results have been shown in a recent series of
1904 patients who underwent elective AAA repair with OR
or EVAR (37.7%). Patients undergoing EVAR had signifi-
cantly lower 30-day (3.1% vs 5.6%, P  .01) and 1-year
mortality rates (8.7% vs 12.1%, P  .018) than patients
having OR. EVAR was associated with a decrease in 30-day
postoperative mortality (P .04). The risk of perioperative
complications was much less after EVAR (15.5% vs 27.7%;
P  .001).37 These short-term benefits are extremely im-
portant in patients who require further treatment for the
concomitant neoplastic condition.
In line with these results, the patients in our series who
had EVAR had a lower operative mortality than those who
had OR, and this advantage was maintained after a mean
follow-up of approximately 3 years. In fact, although the
number of cancer-related deaths in the two groups was
similar, surgically related deaths occurred only in the OR
group.
The difference in AAA size between EVAR and OR
group in our study reflects the selection criteria used for the
EVAR. Evidence in literature shows that patients with
larger aneurysms are less suitable for EVAR,38 and larger
aneurysms are often associated with arterial anatomy that is
less favorable for EVAR.39 It has also been shown that
patients with an AAA 60 mm and a proximal aortic neck
26 mm have worse clinical outcome after EVAR.40 It is
unlikely that the difference in AAA size would have influ-
enced the outcome of the repair, however.
The high incidence of late complications in EVAR
patients reported in the literature raises the concern that its
Fig. Kaplan-Meier life-table curves for cumulative survival rates
for the patients that had endovascular aneurysm repair (EVAR, red
line) and open surgical repair (OR, blue line.)
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However, this is a less important consideration in patients
with AAA who require further intervention for concomi-
tantmalignancy andwho, as a group,may have a shorter life
expectancy than those without malignancy and in whom
the long-term durability of EVAR is relatively less impor-
tant. Furthermore, it is also likely that improvement of
endovascular devices, refined technique, and enhanced op-
erator experience will have an impact on the long-term
outcome of EVAR. In our study, one late graft complica-
tion occurred in the EVAR group, which was successfully
treated. One fatal late graft complication occurred in the
OR group in a patient who underwent a left hemicolectomy
and the AAA repair in one stage.
CONCLUSION
We conclude from these clinical results that EVAR
should be considered as an attractive treatment option in
the treatment of patients with AAA and a concomitant
malignancy. Further experience, and possibly randomized
trials, is required to further assess the role of EVAR in the
management of these challenging patients.
We thank Raimondo Costabile, MSD, for performing
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